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Abstract: Rift Valley fever virus (RVFV) causes large outbreaks of acute febrile and often fatal illness among humans 
and domesticated animals in sub-saharan Africa and the Arabian peninsula. RVFV is a member of the family 
Bunyaviridae, genus Phlebovirus. Like all members of this large virus family, it contains a three-segmented genome of 
negative/ambisense strand RNA, packaged into viral nucleocapsid protein, and enveloped by a lipid bilayer containing 
two viral glycoproteins. During the past years, there was an increased interest in RVFV epidemiology, molecular biology, 
and virulence mechanisms. Here, we will try to provide an overview over the basic features of this significant pathogen, 
and review the latest developments in this highly active research field. 
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INTRODUCTION 
  Rift Valley fever virus (RVFV) is a serious emerging 
pathogen affecting humans and livestock in sub-Saharan 
Africa, Egypt, Yemen, and Saudi Arabia. Since the first 
description of an outbreak in Kenya 1931 [1], recurrent 
epidemics have killed hundreds of thousands of animals, 
more than a thousand humans, and caused significant 
economic losses [2, 3]. To animals, RVFV is mainly 
transmitted by a range of mosquito species (Aedes, 
Anopheles, Culex, Eretmapoites, Mansonia), but has also 
been shown to be transmitted by other vectors e.g. sandflies 
[4, 5]. Infected animals develop necrotic hepatitis, 
hemorrhage and abortion, with death rates up to 100% 
among newborn animals [3]. Humans are often infected by 
close contact with sick animals [6, 7] and the disease is 
associated with symptoms ranging from uncomplicated acute 
febrile illness to retinitis, hepatitis, renal failure, 
meningoencephalitis, severe hemorrhagic disease, and death 
[3]. Although the mortality rate for humans was reported to 
be approximately 2%, in recent outbreaks it went up to 45% 
[8, 9]. The severity of RVFV zoonosis, its capability to cause 
major epidemics among livestock and humans, and the lack 
of efficient prophylactic and therapeutic measures make 
infection with this pathogen a serious public health concern 
not only in endemic, developing countries, but also in many 
non-endemic industrial countries. Authorities have therefore 
listed RVF as a notifiable disease and classified RVFV as a 
BSL-3 or BSL-3+/4 agent respectively, in Europe and in the 
US, and a potential biological weapon [10]. 
  During the past years, there was an increased interest in 
RVFV epidemiology, molecular biology, and virulence 
mechanisms. Here, we will try to provide an overview over 
the basic features of this significant pathogen, and review the 
latest developments in this highly active research field. 
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THE FAMILY BUNYAVIRIDAE 
  RVFV belongs to the genus Phlebovirus, family 
Bunyaviridae [11]. Bunyaviruses are enveloped and have a 
tri-segmented single-stranded RNA genome of negative or 
ambisense polarity. Transcription and replication take place 
in the cytoplasm. The genome segments of bunyaviruses 
encode four structural proteins: the viral polymerase (L) on 
the large (L) segment, two glycoproteins (Gn and Gc) on the 
medium (M) segment, and the viral nucleocapsid protein (N) 
on the smallest (S) segment [12]. RVFV additionally 
expresses two nonstructural proteins encoded on the M 
segment, a 78kDa protein and a 14kDa protein that we 
propose to name NSm1 and NSm2, as suggested initially by 
Gerrard and Nichol [13], and one on the S segment (termed 
NSs). These nonstructural proteins are dispensable for viral 
multiplication in cell culture, but play important roles for 
pathogenesis in vivo [14-17]. 
Virion Structure 
  Early ultrastructural studies by electron microscopy and 
negative staining [18] described RVFV particles measuring 
90-110 nm in diameter. The envelope is composed of a lipid 
bilayer containing the Gn and Gc glycoproteins forming 
surface subunits, 5-8 nm in length, regularly arranged on its 
surface, similar to those reported for the related Uukuniemi 
phlebovirus by von Bonsdorff and Pettersson [19]. The viral 
ribonucleoproteins (RNPs) composed of the three genomic 
segments associated with numerous copies of the 
nucleoprotein N and the RNA dependent RNA polymerase L 
are packaged into the virion. More recent studies by cryo-
electron microscopy [20-22] have changed the former view 
that phleboviruses are pleiomorphic. Instead, these studies 
indicated that the virion is likely to have an icosahedral 
symmetry: the structure of RVFV is surprisingly ordered and 
the surface covered by a shell of 122 glycoprotein capsomers 
arranged in an icosahedral lattice with T=12. A similar 
structure was reported for Uukuniemi virus [23]. For RVFV, 
three-dimensional reconstructions at 2.1 or 2.3 nm resolution 
revealed that the capsomers resemble hollow cylinders Rift Valley Fever Virus  The Open Virology Journal, 2010, Volume 4    9 
situated at five- and six-coordinated positions. Strikingly, 
inside the envelope a layer of RNPs is visible which bends 
the inner leaflet membrane towards the glycoproteins, of 
which even the transmembrane segments are discernible 
[21]. This suggests a strong interaction between the 
cytoplasmic tail of the glycoproteins (most likely Gn) and 
the RNPs which is known to enable packaging of the 
genome into the particles [24, 25]. 
The Viral Genome 
  The three genomic RNA segments of bunyaviruses 
contain untranslated regions (UTRs) at the 3’ and 5’ ends 
which are segment-specific and serve as promoters for 
transcription and replication by the viral polymerase. The 
termini of the UTRs are conserved and form panhandle 
structures [26-28] which give the RNPs a circular 
appearance when observed by electron microscopy [29-31]. 
For RVFV, the L and M segments are of negative polarity 
while the S segment utilizes an ambisense strategy to code 
for both N and NSs [32]. The coding capacity of the genome 
is depicted in Fig. (1A). The general view that only the viral, 
negative-sense genome is incorporated into the mature 
particle must be revised as a small but significant fraction of 
the antigenomes i.e. replicative intermediates have been 
detected in purified RVFV particles [33], confirming past 
studies on Uukuniemi virus [34]. 
Viral Replication Cycle and the Role of Viral Gene 
Products 
Transcription and Replication 
  The general features of RVFV transcription and 
replication are similar to those of other negative stranded 
RNA viruses [35]. During the replication cycle, each 
segment is transcribed into a mRNA and is replicated 
through a process which involves the synthesis of the exact 
copy of the genome, called complementary RNA (cRNA) or 
antigenome. For Phleboviruses, and RVFV in particular, the 
cRNA representing the copy of the S ambisense segment 
serves as template for the synthesis of the NSs mRNA. Since 
some cRNA is also present in the input virus [33], the 
virulence factor NSs is expressed immediately after the virus 
has entered the host cell. Bunyaviral mRNA synthesis in 
general is initiated through a cap-snatching mechanism by 
which host mRNAs are cleaved through an endonuclease 
activity of the L protein [36] to obtain 10 to 18 nucleotide-
long primers for transcription [36-40]. Synthesis of cRNA 
and vRNA does not require an oligonucleotide primer and is 
directly initiated with 5’ nucleoside triphosphates. cRNA 
represents a complete copy of the vRNA, whereas mRNAs 
terminate before the 5’ end of the template. The mechanism 
of the switch between transcription and replication remains 
ill-characterized. Moreover, although RNA-dependent poly-
merase consensus motifs are present in the RVFV L protein 
 
Fig. (1). Genome and expression strategies of RVFV. (A) Schematic representation of the three genomic segments L (large), M (medium) 
and S (small) and the proteins encoded on them. (B) The mRNA transcribed from the M segment contains five in-frame start codons which 
gove rise to the 78kDa and the 14 kDa proteins, as well as some minor products [13]. Scissor indicate host cell protease sites for cleavage of 
the polyproteins. 
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[41], the domains responsible for the different activities have 
not been defined precisely. However, minigenome systems 
have been helpful to analyze some steps in RNA synthesis 
i.e. transcription, replication, transcription termination, and 
packaging. Minigenomes are similar to viral genome 
segments but the viral ORF is replaced by a reporter gene. 
Minigenomes are usually expressed either from T7- or from 
Pol I-based promoter plasmids, or transcribed in vitro and 
transfected as RNA. Early on, studies with minigenomes 
have established that transcription and replication of the 
bunyaviral RNA requires the N and L proteins [42, 43]. 
Together with the vRNA, L and N are needed to reconstitute 
RNPs since, as for all negative stranded genomes, naked 
vRNA cannot be transcribed. Analysis of the RVFV RNPs 
showed that the N protein is able to establish intermolecular 
interactions through several amino-acids located in the N 
terminal region of the protein which are conserved among 
phlebovirus N sequences [44]. The ability of N to form 
oligomers may be a conserved feature in bunyaviruses [45-
48]. The L protein, probably in association with N, is able to 
perform both transcription and replication, excluding the 
possibility that the L protein had to be modified by a third 
viral factor to function as a replicase. For RVFV, the viral 
protein NSs was reported to promote viral RNA replication 
and transcription in a minigenome system [49]. However, 
these experiments were performed in human 293T cells 
expressing T7 polymerase. RNAs produced by the T7 
polymerase contain 5’ triphosphate ends which are strong 
inducers of the antiviral type I interferon (IFN) response [50, 
51, 51a]. 293T cells, like most other cells, are capable to 
respond to 5’triphosphate RNAs, whereas the BHK-derived 
cells used by most researchers to express T7 polymerase are 
unresponsive due to a defect in the RIG-I pattern recognition 
pathway [52]. Moreover, the stimulatory effect of NSs was 
not confirmed in BHK cells (MB, unpublished data) but 
rather inhibited minireplicon activity in a manner similar to 
the NSs of the related viruses Bunyamwera [53] and La 
Crosse [54]. In line with this, when infectious RVFV 
particles were produced by T7-based systems in BHK-
derived cells, RVFV NSs was shown to be either inhibitory 
[55], or irrelevant for generating recombinant viruses [52, 
56]. It is thus conceivable that the observed stimulatory 
effect of RVFV NSs is indirect, namely through the well-
established ability to suppress the antiviral IFN response (see 
below). 
  When compared to each other, the L, M and S segment-
based minigenomes do not express identical levels of 
reporter gene. This indicates differential promoter activities 
associated with the UTRs [57]. Although the mutagenesis 
analysis was not as extensive as the one carried out for 
Uukuniemi virus [58], it appeared that some of the conserved 
UTR nucleotides play an important role in promoter activity 
and the regulation of gene expression [59]. 
  Bunyavirus mRNAs (except for Sin Nombre hantavirus 
[60]) are not polyadenylated. They have a shortened 3’ end 
relative to the full-length cRNA, suggesting that a specific 
termination signal is recognized during transcription. 
Preliminary data had indicated that a conserved motif is 
present in the intergenic region of the S segment of the 
phleboviruses Toscana (TOSV), Sandfly fever Sicilian   
 
(SFSV), and RVFV [32, 38]. Albarino et al. [61] mapped 
precisely the 3’ ends of the L, M, N and NSs mRNAs of 
TOSV, SFSV and RVFV, and identified a sequence motif 
3’-C1-3GUCG/A-5’ which is conserved on the M and S 
segments of phleboviruses. The phleboviral L segment 
mRNA, by contrast, was found to have a full-length 3’ end. 
Ikegami  et al. [62] came to similar conclusions for the 
termination of the M and S segment mRNAs of RVFV, but 
claimed that the L mRNA lacks the last 16-41 nucleotides 
when compared to the full-length cRNA copy, and that the 
termination signal corresponds to two 13-nucleotide-long 
complementary sequences present in the 5’ non-coding 
region of the L genomic segment. 
Glycoproteins and Particle Formation 
  The RVFV envelope glycoproteins mediate particle entry 
into cells through receptors which, like for most 
bunyaviruses, remain to be identified. RVFV entry is 
predicted to employ a class II fusion mechanism that is 
activated by low pH following endocytosis of the virion [63]. 
The RVFV M segment encodes Gn (encoded by amino-
terminal sequences) and Gc (encoded by carboxy-terminal 
sequences) as well as two nonstructural proteins NSm1 
(78kDa) and NSm2 (14kDa). The NSm1 and NSm2 proteins 
are produced by alternative use of the first and second of the 
5 in-frame AUG codons, respectively, which are present at 
the 5’ end of the M mRNA i.e. upstream of the Gn sequence 
(Fig. 1B). The role of these proteins will be discussed further 
below. 
  Like all bunyaviruses, RVFV particles usually bud into 
the lumen of the Golgi apparatus [35]. Budding at the plasma 
membrane was however observed in rat hepatocytes [64]. 
Both RVFV Gn and Gc localize to the Golgi apparatus when 
expressed together from polyprotein-expressing plasmids 
[65]. When expressed alone, Gn could be transported to the 
Golgi apparatus due to a specific Golgi localization motif, 
whereas Gc localized to the endoplasmic reticulum (ER) due 
to the presence of a specific ER retention signal [66]. This 
suggests that, similar to other bunyaviruses [67, 68], Gc 
moves to the Golgi apparatus via  its physical association 
with Gn. 
  The minigenome systems expressing a reporter gene 
were also useful to investigate viral packaging activity. In 
that case, the glycoproteins were co-expressed with the 
transcription machinery to allow formation of viral like 
particles (VLPs) released into the medium [69]. When 
observed by electron microscopy and negative staining, these 
particles resembled RVFV particles in size and morphology. 
They were able to infect naïve cells and to undergo the first 
step of the replication cycle, i. e. primary transcription. If 
both L and N were provided in trans, replication of 
minigenomes also occured [69]. Using these VLPs, it was 
shown that the interferon-induced antiviral protein MxA 
inhibits both primary and secondary transcription of RVFV. 
Interestingly, similar RVFV VLPs were produced in insect 
cells infected with a dual baculovirus vector expressing 
Gn/Gc and N [70]. Another vector expressing N and Gc only 
resulted in particles which were more pleiomorphic than full-
fledged VLPs and RVFV particles, suggesting that both Gn 
and Gc contribute to the assembly process and likely interact 
with N. Rift Valley Fever Virus  The Open Virology Journal, 2010, Volume 4    11 
Reverse Genetics 
  Reverse genetics systems allow to freely manipulate the 
viral genome and to dissect individual steps in the viral 
multiplication cycle. The minireplicon and VLP systems 
mentioned above were proven useful to study primary 
transcription, cell-autonomous antiviral responses, genome 
replication, and RNP packaging [49, 57, 69]. Fully 
infectious, recombinant virus particles can be recovered from 
cloned cDNA plasmids if the minireplicon is replaced by 
constructs for the full-length viral RNA segments. This 
technique was first established for Bunyamwera virus, the 
prototype of the Bunyaviridae [71, 72], followed by the 
related La Crosse virus [73]. These rescue systems were 
based on T7-transgenic cells to express the constructs for the 
viral genome segments and the helper proteins N and L. T7 
systems were also used to recover recombinant RVFV [15, 
55], but promoters for the cellular pol I could also be used to 
express the genome segments [52, 56]. This indicates that 
RVFV, a cytoplasmic virus, does not contain critical 
sequences e.g. cryptic splice sites, which could interfere with 
nuclear transcription of the genome. In fact, T7- and Pol 
I/Pol II-driven systems were shown to be of similar 
efficiency [52]. It should be noted that the Pol I system 
requires co-transfection of the N and L helper plasmids, 
whereas in the T7 system helper plasmids are either not 
necessary or even inhibitory. However, in T7-driven systems 
the T7 polymerase has to be provided in trans, usually by 
stably expressing cell lines. As outlined above, the cell lines 
used for T7 expression [55, 74] are deficient in the RIG-I 
pathway [52] which would normally respond to the 5’ 
triphosphorylated T7 transcripts with the production of the 
antiviral IFNs. 
  Depending on the laboratory which developed the rescue 
system, the genetic backbone of the recombinant virus was 
based either on the attenuated strain MP12 [55, 56], or the 
virulent strains ZH501 [15] or ZH548 [52, 56]. 
Role of the Non-Structural Proteins 
  The establishment of reverse genetics systems has 
opened the door for studies of RVFV molecular biology and 
pathogenesis which were unthinkable a few years ago. 
The Role of NSs in Virulence 
  NSs of RVFV forms a ribbon-like filament in the nucleus 
[12] (Fig. 2). This feature is unexpected for a virus 
replicating in the cytoplasm. Moreover, it is particular to 
RVFV and not shared with NSs proteins of other 
bunyaviruses. NSs was characterized as a major virulence 
factor counteracting the antiviral IFN system [16, 75, 76]. It 
has become clear meanwhile that NSs is a multifunctional 
protein inhibiting cellular transcription in general and 
suppressing two different arms of the IFN response, namely 
(i) IFN induction by a specific, early, mechanism (ii) the 
antiviral protein PKR. 
  With respect to specific suppression of IFN induction, the 
cellular protein SAP30 was identified as interacting with 
NSs. SAP30 belongs to the Sin3A/NCoR/HDAC repressor 
complexes intervening in gene transcription regulation [77]. 
Moreover, it is known that SAP30 interacts directly with 
YY1 [78], a transcription factor involved in the regulation of 
expression of numerous genes, including IFN- [79]. 
Through a series of co-immunoprecipitation, confocal 
microscopy and chromatin immunoprecipitations, it was 
demonstrated that NSs, SAP30, YY1 and Sin3A-associated 
corepressors are recruited on the IFN- promoter inhibiting 
CBP recruitment, histone acetylation and transcriptional 
activation [77]. Using reverse genetics, a recombinant 
ZH548 in which NSs was deleted of the SAP30 interaction 
domain was produced. In contrast with the wt virus, this 
mutant, ZH548-NSs210-230, induced IFN- expression 
and was unable to kill mice. Although this mutant protein 
was still located in the nucleus, it was not able to form 
filaments. Further analyses on the wt NSs filament indicated 
that, even though cellular DNA is mostly excluded from the 
filament, heterochromatin clusters of pericentromeric gamma 
satellite sequences appeared intimately associated with NSs 
[79a]. This results in a high incidence of nuclear anomalies, 
translating chromosome cohesion and segregation defects 
which could contribute to RVFV pathology. 
  NSs also suppresses cellular gene expression by a more 
general mechanism which relies on the interaction with the host 
cell protein p44. p44 is a subunit of the TFIIH basal 
transcription factor and becomes sequestered into the NSs 
 
Fig. (2). RVFV NSs forms a filamentous structure in the nucleus. Confocal microscopy picture showing a section of a L929 cell nucleus 
infected by ZH548 and stained with the DNA intercalating dye ToPro3 (red), with anti-NSs antibodies (green) and merge. The cellular DNA 
is predominantly excluded from the filament (from Mansuroglu et al., J. Virol. in press). 12    The Open Virology Journal, 2010, Volume 4  Bouloy and Weber 
filamentous structure characteristic of RVFV infection [80]. As 
a consequence, TFIIH cannot assemble and its concentration 
drops rapidly, explaining the drastically reduced transcriptional 
activity of cells infected with RVFV. Interestingly, NSs thus 
functions as a general inhibitor of Pol II as well as Pol I, since 
TFIIH is involved in transcription by both these host 
polymerases. Inhibition of TFIIH and hence general 
transcription is a relatively late event occurring after 8 h of 
infection, whereas the specific inhibition of IFN- transcription 
(mediated by SAP30 recruitment) is in place as early as 3-4 h 
after infection. 
  Very recently, a novel function of NSs was described, the 
targeting of the antiviral, IFN-induced protein kinase PKR [81, 
82]. PKR is a serine-threonine kinase activated by viral RNAs 
and mediating a stop of translation [83]. NSs-dependent 
degradation is specific for PKR and occurs through the 
proteasome. Hence, cells infected with RVFV are devoid of 
PKR, whereas PKR was clearly detected and activated by 
infection with NSs-deleted virus strains e.g. Clone 13. This anti-
PKR activity is important for viral replication and pathogenesis, 
since mice expressing PKR clear infection by Clone 13, 
whereas knockout mice lacking PKR succumb to Clone 13 and 
develop high virus titers in the liver [81]. The fact that NSs itself 
provokes a PKR-knockout-like situation is likely to contribute 
to the pathogenicity of wt RVFV. Interestingly, it was also 
observed that this activity is specific to RVFV NSs and not 
shared with other Phleboviruses like Sandfly fever Sicilian virus 
or the orthobunyavirus La Crosse [81]. 
  Altogether, it appears that NSs has multiple functions to 
counteract the IFN system, either at the transcriptional level or 
at the translational level by degrading PKR. 
The Role of the NSm Protein as a Virulence Factor and a 
Suppressor of Virus-Induced Apoptosis 
  The biological function of the NSm1 and NSm2 proteins 
was addressed by producing RVFV mutants with either a 
deletion in the pre-Gn region [15, 84] or point mutations in the 
start codons of the two respective reading frames [17]. In all 
cases, virus growth in cell culture was similar to the parental 
viruses. However, when the pre-Gn deletion was introduced 
into the MP12 strain, plaques were larger than for the parental 
MP12 strain and a more extensive apoptosis due to elevated 
caspase activity was observed [84]. Curiously, a similar deletion 
introduced into the virulent strain ZH501 did not show any 
differences in plaque size, and an increase in apoptosis was not 
reported [15]. Moreover, if the AUG-inactivating point 
mutations in the pre-Gn region, which abrogated the NSm1 and 
NSm2 expression, were introduced into the MP12 background, 
they also led to a plaque phenotype indistinguishable from the 
parental virus [17]. The differences between the pre-Gn deletion 
and the AUG point mutant of MP12 can be explained by 
residual expression of a truncated version of the NSm1 protein, 
the 73-kDa protein [84]. Why this is not happening for ZH501 
remains to be investigated. In any case, all available data are 
congruent in indicating that the NSm1 and NSm2 proteins of 
RVFV are dispensable for virus growth in cell culture. 
NEW INSIGHTS FOR THE DEVELOPMENT OF 
VACCINES 
  A natural virus, Clone 13, lacks more than 70% of the 
coding sequence for the IFN antagonist NSs and is avirulent for 
mice, sheep and cattle, but highly immunogenic [85]. The anti-
IFN function of NSs is conserved among the bunyaviruses and 
has been described for another phlebovirus, Punta Toro virus 
[86] as well as for the orthobunyaviruses Bunyamwera [87, 88] 
and La Crosse [89]. NSs is thus a prime target for the 
development of attenuated virus strains. In addition, deletion of 
the NSm2 gene confers an additional level of safety. NSm2 was 
shown to severely hamper immune responses to a DNA vaccine 
construct encoding the M segment [90]. The mechanism behind 
this interesting observation is not clear so far. In contrast to the 
full-length construct which conferred only poor 
immunogenicity, NSm2-deleted M segment cDNA was very 
immunogenic and gave 100 % survival rate upon challenge 
[90]. With respect to live viruses, RVFV mutants lacking NSm2 
are somewhat attenuated compared to wt RVFV but can still 
cause either acute lethal hepatic necrosis or delayed lethal 
neurologic disease [14]. NSs-NSm2 double deletion mutants 
induced robust anti-RVF virus antibody responses and 100% 
protection from a lethal challenge [91]. Replacement of NSs by 
a marker gene e.g. GFP, could be helpful to screen antivirals 
[91]. Based on the absence of NSs-specific antibodies, an 
ELISA was developed to distinguish infected from vaccinated 
animals [92]. 
  An even more radical approach is represented by 
transcriptionally active RVFV VLPs which were produced by 
reverse genetics [69]. The VLPs resemble authentic RVFV 
particles and are able to express a reporter gene, but lack all the 
genes necessary for virus spread or pathogenesis. Three 
injections of VLPs induced neutralizing antibodies and were 
shown to be highly protective against a lethal challenge [93]. 
  Thus, the recently gained knowledge on RVFV molecular 
biology already proved useful for the understanding and 
development of modern vaccine candidates [94, 95], and future 
findings will certainly help to further improve our repertoire of 
strategies to combat this important pathogen. 
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